Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Fiche publication
Date publication
septembre 2018
Journal
The Lancet. Haematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr FEUGIER Pierre
Tous les auteurs :
Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G,
Lien Pubmed
Résumé
Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard front-line treatment for follicular lymphoma. The combination of lenalidomide and rituximab has shown high efficacy in relapsed or refractory and untreated follicular lymphoma. We aimed to evaluate the safety and activity of the combination of lenalidomide and R-CHOP (R2-CHOP) in previously untreated patients with high burden follicular lymphoma.
Mots clés
Aged, Antibodies, Monoclonal, Murine-Derived, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cyclophosphamide, therapeutic use, Doxorubicin, therapeutic use, Female, Humans, Kaplan-Meier Estimate, Lenalidomide, Lymphoma, Follicular, drug therapy, Male, Middle Aged, Prednisone, therapeutic use, Thalidomide, analogs & derivatives, Tumor Burden, drug effects, Vincristine, therapeutic use
Référence
Lancet Haematol. 2018 Sep;5(9):e403-e410